Tag: ABBV
-
3 Top Dividend ETFs to Buy for Income, Stability, and Long-Term Growth
Looking for income and stability? These three dividend ETFs offer reliable yields, quality holdings, and long-term growth potential.
-
AbbVie vs. JNJ: Which Biopharma Stock Wins in 2026?
Biopharma stocks may benefit from sector rotation. AbbVie and Johnson & Johnson deserve a close look, but they are not the same trade.
-
3 High-Yield Dividend ETFs to Protect Your Portfolio From Market Volatility
In times of market volatility, investors can strengthen their portfolios by incorporating diversified, income-producing dividend ETFs.
-
3 Safe ETFs to Buy Now as Market Volatility Rises
Instead of sitting in cash or trying to time the market, investors may find opportunities in safe ETFs that follow strategies favored by Warren Buffett.
-
AbbVie Q1 2026 Earnings: Skyrizi and Rinvoq Drive Record Growth
AbbVie’s Q1 results confirm that its post-Humira growth platform is accelerating, and management’s decision to raise full-year guidance reflects that optimism.
-
Protect Your Portfolio with 3 High-Yielding Dividend ETFs
In uncertain markets, dividend ETFs —especially those emphasizing companies with long histories of growing payouts—can help anchor your portfolio.
-
3 ETFs to Build Income and Wealth Over Time
Exchange-traded funds (ETFs) remain an efficient way for investors to build long-term wealth with steady dividend income that can compound over time.
-
These 3 Safe ETFs Will Help Keep Your Portfolio Secure
Instead of trying to time every headline, investors can focus on safe ETFs to build resilience and stability in their portfolios
-
5 Retirement Income ETFs That Can Deliver a Monthly Paycheck
For many investors, the goal of retirement isn’t just growth — it’s reliable income. That’s why retirement income ETFs and monthly income ETFs have become essential tools for building passive income in retirement without having to sell assets during market downturns. After spending years building up your nest egg, you want to step into the…
-
Trade Alert: AbbVie (ABBV) Stock Could Be Mispriced Ahead of Earnings
Volatility skew ahead of the February-month expiration date potentially points to an upside opportunity for ABBV stock.